Related Experiment Video
Updated: May 30, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Stroke in atrial fibrillation: epidemiology and thromboprophylaxis
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk
Insights
Atrial fibrillation (AF) stroke risk can be reduced with oral anticoagulation (OAC). New OACs and improved risk assessments aim to optimize thromboprophylaxis and prevent AF-related strokes.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common heart rhythm disorder linked to significant stroke and thromboembolism risks.
- Oral anticoagulation (OAC) effectively prevents AF-related stroke, yet its use remains suboptimal due to limitations of current vitamin K antagonist (VKA) therapies.
- Newer OAC agents offer advantages over VKAs, presenting an opportunity to improve thromboprophylaxis and reduce stroke incidence.
Purpose of the Study:
- To provide a comprehensive overview of stroke in AF, focusing on clinical epidemiology.
- To review current stroke and bleeding risk assessment strategies for AF patients.
- To examine the current provision and future directions of thromboprophylaxis in AF management.
Main Methods:
- Literature review of epidemiological data and clinical trial evidence on AF and stroke.
- Analysis of current guidelines and clinical practices for OAC and thromboprophylaxis.
- Evaluation of emerging OAC agents and risk stratification tools.
Main Results:
- AF is a major cause of stroke, but effective prevention is achievable with OAC.
- Suboptimal thromboprophylaxis is partly due to VKA limitations; newer OACs show promise.
- Enhanced stroke and bleeding risk assessments are crucial for personalized OAC decisions.
Conclusions:
- Optimizing OAC use in AF, aided by novel agents and refined risk assessment, is key to reducing stroke burden.
- Improved risk stratification can identify patients who truly need anticoagulation and those who do not.
- The review highlights the need for better clinical decision-making tools for AF thromboprophylaxis.
Abstract:
Atrial fibrillation (AF) is the commonest sustained cardiac rhythm disorder, which is associated with a substantial risk of mortality and morbidity arising from stroke and thromboembolism. Extensive epidemiological evidence and robust data from clinical trials have shown that stroke and thromboembolism in AF can be prevented by oral anticoagulation (OAC). Despite this evidence and guidelines, appropriate thromboprophylaxis is still suboptimal, and this is partly due to the only OAC agent being available is the vitamin K antagonist class of drugs (e.g. warfarin) that has many limitations and disadvantages. With the availability of new OAC agents that avoid the disutility of the vitamin K antagonists, it is hoped that greater use of OAC would allow more effective thromboprophylaxis and have a great impact on preventing strokes related to AF. Additionally, stroke risk assessments need to evolve such that they are better at identifying the 'truly low risk' subjects who do not need antithrombotic therapy, whilst all other patients with ≥ 1 stroke risk factors can be considered for OAC. The availability of comprehensive stroke and bleeding risk assessments would enable us to make informed decisions in everyday clinical practice. The aim of the review article is to provide a state-of-the-art overview of the clinical epidemiology of stroke in AF, stroke (and bleeding) risk assessments and the current provision of thromboprophylaxis for patients with AF.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction

